Table 5.
Univariate and multivariate analysis of prognostic factors for OS.
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95%CI) | P value | HR (95%CI) | P value | |
| Age | 0.976(0.952~1.001) | 0.060 | 1.004(0.980~1.028) | 0.753 |
| Gender | 0.096 | 0.168 | ||
| Male | Reference | Reference | ||
| Female | 0.366(0.112~1.195) | 0.589(0.277~1.250) | ||
| ECOG performance | 0.001 | 0.276 | ||
| 0 | Reference | Reference | ||
| 1 | 2.926(1.578~5.427) | 0.735(0.422~1.279 | ||
| Number of tumors | 0.009 | 0.041 | ||
| >3 | Reference | Reference | ||
| ≤3 | 4.785(1.476~15.513) | 2.250(1.034~4.894) | ||
| HBV infection | 0.345 | |||
| No | Reference | |||
| Yes | 0.654(0.271~1.577) | |||
| Child-Pugh class | 0.299 | |||
| A | Reference | |||
| B | 0.651(0.290~1.463) | |||
| BCLC stage | 0.048 | 0.040 | ||
| B | Reference | Reference | ||
| C | 1.911(1.006~3.630) | 1.738(1.025~2.947) | ||
| Extrahepatic metastases | 0.120 | |||
| Yes | Reference | |||
| No | 0.578(0.325~1.453) | |||
| AFP (ng/ml) | 0.734 | |||
| >400 | Reference | |||
| ≤400 | 0.901(0.494~1.643) | |||
| Tumor size (cm) | 1.007(0.943~1.076) | 0.827 | ||
| PLR | 1.001(0.996~1.006) | 0.677 | ||
| NLR | 1.002(0.895~1.166) | 0.750 | ||
| ALT(IU/L) | 1.007(0.996~1.019) | 0.216 | ||
| AST (IU/L) | 1.006(0.996~1.016) | 0.243 | ||
| Albumin (g/dL) | 1.037(0.970~1.109) | 0.290 | ||
| TB (µmol/L) | 1.026(0.977~1.077) | 0.303 | ||
| PT(s) | 1.018(0.897~1.156) | 0.783 | ||
| TACE Sessions | 1.035(0.933~1.148) | 0.514 | ||
| Treatment | <0.001 | 0.003 | ||
| TACE-LEN | Reference | Reference | ||
| TACE-LEN-C | 0.171(0.072~0.403) | 0.382(0.201~0.725) | ||
HR, hazard ratio; CI, confidence interval; BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B; AFP, alpha-fetoprotein; ALT, alanine transaminase; AST, aspartate aminotransferase; HCC, hepatocellular carcinoma; OS, overall survival; TACE-LEN, transcatheter arterial chemoembolization with Lenvatinib; TACE-LEN-C, transcatheter arterial chemoembolization with Lenvatinib plus camrelizumab. Bold values signifies important information in the Statistical analysis section.